Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

Sentiment:

Merger Completion / Insider Disposal


Assertio Holdings, Inc. executive Sam Schlessinger reports the disposal of all equity holdings following the company's acquisition by Zydus Worldwide DMCC.

Summary

  • Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC for $23.50 per share in cash.
  • The merger became effective on June 16, 2026, resulting in Assertio becoming a wholly owned subsidiary of Zydus.
  • Reporting person Sam Schlessinger, EVP and General Counsel, disposed of 14,738 shares of common stock.
  • All outstanding restricted stock units (25,748) and stock options were cancelled and converted into cash payments based on the $23.50 offer price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative step of a completed corporate acquisition.

Positives

  • Shareholders received a definitive cash exit at $23.50 per share.
  • Unvested restricted stock units were accelerated and fully vested prior to the merger completion.
  • In-the-money stock options were converted into cash payments for the reporting person.

Negatives

  • Stock options with exercise prices equal to or greater than the $23.50 offer price were cancelled without any cash payment.
  • The company is no longer a publicly traded entity.

Risks

  • The company has ceased to be an independent public entity, eliminating future upside potential for public shareholders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further public guidance will be provided.

Management Comments

  • The transactions reported reflect the completion of the merger agreement dated May 13, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation in the pharmaceutical sector, with Zydus expanding its U.S. footprint by absorbing Assertio's portfolio.

Comparison to Industry Standards

  • The all-cash acquisition structure is standard for mid-cap pharmaceutical takeovers.
  • The conversion of unvested equity into cash upon change-of-control is consistent with typical executive compensation agreements in the industry.

Stakeholder Impact

  • Shareholders have been cashed out at the agreed offer price.
  • Employees and management are now part of the Zydus organization.

Next Steps

  • Delisting of Assertio Holdings, Inc. common stock from public exchanges.

Key Dates

DateDescription
05/13/2026Date of the Agreement and Plan of Merger.
06/16/2026Effective time of the merger and date of the reported transactions.

Keywords

Assertio Holdings, ASRT, Merger, Acquisition, Zydus, Form 4, Insider Transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.